Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research.
Tafalgie Therapeutics has raised $14.1M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Tafalgie Therapeutics's investors include Bpifrance, European Innovation Council, EIC Accelerator, Incubateur Impulse.
Tafalgie Therapeutics is headquartered in Marseille, France.
Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research.
Tafalgie Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tafalgie Therapeutics — Funding & Investors." VCBacked, September 15, 2025, https://www.vcbacked.co/company/tafalgie-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Tafalgie Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tafalgie-therapeutics
{{cite web |title=Tafalgie Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tafalgie-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated